Should I buy or sell Cassava Sciences stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cassava Sciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SAVA shares. View SAVA analyst ratings or view top-rated stocks .

What is Cassava Sciences' stock price target for 2024?

1 Wall Street research analysts have issued 12 month target prices for Cassava Sciences' stock. Their SAVA share price targets range from $28.00 to $124.00. On average, they expect the company's share price to reach $76.00 in the next year. This suggests a possible upside of 265.4% from the stock's current price. View analysts price targets for SAVA or view top-rated stocks among Wall Street analysts .

How have SAVA shares performed in 2023?

Cassava Sciences' stock was trading at $29.54 at the beginning of 2023. Since then, SAVA stock has decreased by 29.6% and is now trading at $20.80. View the best growth stocks for 2023 here .

When is Cassava Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024. View our SAVA earnings forecast .

How were Cassava Sciences' earnings last quarter?

Cassava Sciences, Inc. (NASDAQ:SAVA) released its quarterly earnings results on Tuesday, November, 7th. The company reported ($0.61) EPS for the quarter, topping analysts' consensus estimates of ($0.90) by $0.29.

What ETFs hold Cassava Sciences' stock?

ETFs with the largest weight of Cassava Sciences (NASDAQ:SAVA) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN) , SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF (PILL) . iShares U.S. Pharmaceuticals ETF (IHE) .

When did Cassava Sciences' stock split?

Cassava Sciences's stock reverse split on Wednesday, May 10th 2017. The 1-7 reverse split was announced on Monday, May 8th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 9th 2017. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

What other stocks do shareholders of Cassava Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cassava Sciences investors own include Inovio Pharmaceuticals (INO) , NVIDIA (NVDA) , Novavax (NVAX) , Sorrento Therapeutics (SRNE) , Advanced Micro Devices (AMD) , NIO (NIO) , DURECT (DRRX) , Tesla (TSLA) , OPKO Health (OPK) and Alibaba Group (BABA) .

Who are Cassava Sciences' major shareholders?

Cassava Sciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Gallacher Capital Management LLC (1.37%), Northern Trust Corp (0.89%), Charles Schwab Investment Management Inc. (0.73%), SG Americas Securities LLC (0.66%), Barclays PLC (0.00%) and Bank of New York Mellon Corp (0.32%). Insiders that own company stock include Eric Schoen, James William Kupiec, Richard Barry and Sanford Robertson. View institutional ownership trends .

How do I buy shares of Cassava Sciences?

Shares of SAVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Positive News SentimentPositive News

Cassava Sciences Stock Price, News & Analysis (NASDAQ:SAVA)

$20.80

-0.03 (-0.14%)

(As of 12/1/2023 ET)

Compare

Today's Range: $20.67
▼
$21.30
50-Day Range: $12.64
▼
$24.24
52-Week Range: $12.32
▼
$45.43

Volume: 591,297 shs
Average Volume: 838,388 shs
Market Capitalization: $877.14 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $76.00

Cassava Sciences MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 265.4% Upside
$76.00 Price Target
Short Interest: Bearish
36.80% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.82
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.22) to $1.18 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.17 out of 5 stars

Medical Sector

434th out of 952 stocks

Pharmaceutical Preparations Industry

200th out of 448 stocks

3.5

Analyst's Opinion

Consensus Rating
Cassava Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $76.00, Cassava Sciences has a forecasted upside of 265.4% from its current price of $20.80.
Amount of Analyst Coverage
Cassava Sciences has received no research coverage in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
36.80% of the float of Cassava Sciences has been sold short.
Short Interest Ratio / Days to Cover
Cassava Sciences has a short interest ratio ("days to cover") of 11.3, which indicates bearish sentiment.
Change versus previous month
Short interest in Cassava Sciences has recently decreased by 8.94%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Cassava Sciences does not currently pay a dividend.
Dividend Growth
Cassava Sciences does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Cassava Sciences has received a 74.60% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for Alzheimer" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Cassava Sciences is -0.82.

3.3

News and Social Media Coverage

News Sentiment
Cassava Sciences has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Cassava Sciences this week, compared to 3 articles on an average week.
Search Interest
51 people have searched for SAVA on MarketBeat in the last 30 days. This is an increase of 28% compared to the previous 30 days.
MarketBeat Follows
Only 7 people have added Cassava Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -42% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cassava Sciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 9.00% of the stock of Cassava Sciences is held by insiders.
Percentage Held by Institutions
Only 27.19% of the stock of Cassava Sciences is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Cassava Sciences are expected to grow in the coming year, from ($2.22) to $1.18 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Cassava Sciences is -9.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cassava Sciences is -9.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Cassava Sciences has a P/B Ratio of 5.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Cassava Sciences Stock (NASDAQ:SAVA)

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.

SAVA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SAVA Stock News Headlines

November 23, 2023 | morningstar.com

Cassava Sciences Inc SAVA

November 22, 2023 | finance.yahoo.com

7 High-Risk, High-Reward Stocks for the Extreme Contrarian

December 2, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 9, 2023 | finance.yahoo.com

Cassava Sciences, Inc. (NASDAQ:SAVA): Is Breakeven Near?

November 8, 2023 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Cassava Sciences (SAVA), CymaBay Therapeutics (CBAY)

November 8, 2023 | marketwatch.com

IonQ Announces Third Quarter 2023 Financial Results

November 8, 2023 | markets.businessinsider.com

Ginkgo Bioworks Reports Third Quarter 2023 Financial Results

November 7, 2023 | msn.com

Cassava Sciences Q3 costs rise amid late-stage Alzheimer’s program

December 2, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.

November 7, 2023 | msn.com

Cassava Sciences GAAP EPS of -$0.61 beats by $0.29

November 7, 2023 | finance.yahoo.com

Cassava Sciences Reports Third Quarter 2023 Financial and Operating Results

November 7, 2023 | finance.yahoo.com

Cassava Sciences Inc (SAVA) Reports Q3 2023 Financial Results

November 6, 2023 | msn.com

Cassava Sciences fully enrolls Phase 3 program for Alzheimer’s candidate

November 6, 2023 | finance.yahoo.com

Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer’s Disease

November 3, 2023 | msn.com

Cassava Sciences' Simufilam Does Not Appear To Be Effective Against Alzheimer's Disease

October 31, 2023 | finance.yahoo.com

1 Big Red Flag to Fear When a Stock Is Down

October 30, 2023 | msn.com

Cassava Sciences: My Bullish Take On Biomarkers And CTAD Data

October 28, 2023 | nytimes.com

CUNY Halts Investigation of Alzheimer’s Researcher

October 25, 2023 | markets.businessinsider.com

Why Cassava Sciences Stock Surged Today

October 25, 2023 | msn.com

Cassava Sciences gains after safety data for Alzheimer’s candidate

October 25, 2023 | finance.yahoo.com

MRI Data Suggest Simufilam is Not Associated with Amyloid-related Imaging Abnormalities (ARIA)

October 17, 2023 | benzinga.com

Investigation of Cassava Sciences, Inc. (SAVA) Announced by Holzer & Holzer, LLC

October 16, 2023 | dailymail.co.uk

$500m Alzheimer's drug scandal: NY scientist behind NIH-funded therapy busted for allegedly manipulating data in 20 research papers - now there are calls for trials to be cut off

October 14, 2023 | nytimes.com

Scientists Investigating Alzheimer’s Drug Faulted in Leaked Report

October 13, 2023 | msn.com

Cassava stock falls 15% in wake of negative report on CUNY researcher

October 13, 2023 | bizjournals.com

Leaked report brings new scrutiny on Alzheimer’s drug developed by Austin company

October 13, 2023 | wsj.com

Cassava Stock Sinks After University Investigation Into Scientist

See More Headlines

Receive SAVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cassava Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/07/2023
Today: 12/02/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/27/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:SAVA
CUSIP: N/A
CIK: 1069530
Web: www.cassavasciences.com
Phone: (512) 501-2444
Fax: 512-501-0414
Employees: 26
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $76.00
High Stock Price Target: $124.00
Low Stock Price Target: $28.00
Potential Upside/Downside: +265.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.29)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-76,250,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -49.83%
Return on Assets: -46.40%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 8.62
Quick Ratio: 8.62

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.68 per share
Price / Book: 5.65

Miscellaneous

Outstanding Shares: 42,170,000
Free Float: 38,378,000
Market Cap: $877.14 million
Optionable: Not Optionable
Beta: -0.03

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Mr. Remi Barbier (Age 63)
Founder, Chairman, President & CEO
Comp: $1.11M
Mr. Eric J. Schoen (Age 55)
Chief Financial Officer
Comp: $426.61k
Mr. R. Christopher Cook (Age 59)
Senior VP, Company Secretary & General Counsel
Comp: $457.64k
Dr. James W. Kupiec M.D. (Age 70)
Chief Medical Officer
Comp: $400k
Dr. George Thornton
Senior Vice President of Technology
Mr. Michael Zamloot
Senior Vice President of Technical Operations
Dr. Michael Marsman Pharm.D.
Senior Vice President of Regulatory Affairs
Dr. Lindsay H. Burns Ph.D.
Senior Vice President of Neuroscience

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SAVA Stock Analysis - Frequently Asked Questions

Should I buy or sell Cassava Sciences stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cassava Sciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SAVA shares.
View SAVA analyst ratings or view top-rated stocks.
What is Cassava Sciences' stock price target for 2024?: 1 Wall Street research analysts have issued 12 month target prices for Cassava Sciences' stock. Their SAVA share price targets range from $28.00 to $124.00. On average, they expect the company's share price to reach $76.00 in the next year. This suggests a possible upside of 265.4% from the stock's current price.
View analysts price targets for SAVA or view top-rated stocks among Wall Street analysts.
How have SAVA shares performed in 2023?: Cassava Sciences' stock was trading at $29.54 at the beginning of 2023. Since then, SAVA stock has decreased by 29.6% and is now trading at $20.80.
View the best growth stocks for 2023 here.
When is Cassava Sciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our SAVA earnings forecast.
How were Cassava Sciences' earnings last quarter?: Cassava Sciences, Inc. (NASDAQ:SAVA) released its quarterly earnings results on Tuesday, November, 7th. The company reported ($0.61) EPS for the quarter, topping analysts' consensus estimates of ($0.90) by $0.29.
What ETFs hold Cassava Sciences' stock?: ETFs with the largest weight of Cassava Sciences (NASDAQ:SAVA) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF (PILL).iShares U.S. Pharmaceuticals ETF (IHE).

When did Cassava Sciences' stock split?: Cassava Sciences's stock reverse split on Wednesday, May 10th 2017. The 1-7 reverse split was announced on Monday, May 8th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 9th 2017. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.
What other stocks do shareholders of Cassava Sciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Cassava Sciences investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Novavax (NVAX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), NIO (NIO), DURECT (DRRX), Tesla (TSLA), OPKO Health (OPK) and Alibaba Group (BABA).
Who are Cassava Sciences' major shareholders?: Cassava Sciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Gallacher Capital Management LLC (1.37%), Northern Trust Corp (0.89%), Charles Schwab Investment Management Inc. (0.73%), SG Americas Securities LLC (0.66%), Barclays PLC (0.00%) and Bank of New York Mellon Corp (0.32%). Insiders that own company stock include Eric Schoen, James William Kupiec, Richard Barry and Sanford Robertson.
View institutional ownership trends.
How do I buy shares of Cassava Sciences?: Shares of SAVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:SAVA) was last updated on 12/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial